Strategic Acquisition FORMEL SKIN has recently been involved in high-profile M&A activity, with acquisitions by Manual in 2025 and Joinvoy in 2026, signaling a market consolidation trend. This creates potential upsell or integration opportunities with acquiring platforms seeking to expand digital dermatology capabilities and cross-sell complementary care services.

Digital Dermatology Platform As a Berlin-based HealthTech startup delivering online medical treatments via physician-guided programs, FORMEL SKIN demonstrates a scalable model for remote dermatology care. This aligns with demand from clinics and payers for telemedicine solutions, presenting opportunities to license technology, partner on care pathways, or provide white-labeled services.

Growth Financing With $40M funding raised and revenue in the low-to-mid eight-figure range, FORMEL SKIN has capital for scaling operations, expanding market presence, and investing in marketing tech, patient acquisition funnels, and analytics. This creates opportunities to offer performance marketing services, data-driven patient engagement tools, or enterprise software integrations.

VC Backing Backed by notable early-stage VCs Cherry Ventures and Heartcore Capital, the company has access to strategic networks and potential co-selling opportunities. Sales teams can leverage investor-mentored introductions, potential partnerships, and credibility when approaching hospitals, clinics, and pharmacies.

Pharmacy-Led Treatments The treatment plan is created by pharmacies and shipped monthly, indicating a fully integrated supply chain. This presents opportunities to discuss pharmaceutical fulfillment partnerships, logistic enhancements, pharmacy network expansion, and value-added services like patient adherence programs or real-time dosage optimization.